報價延遲最少15分鐘:2026/01/07 17:21 EST
盤後時段
|
||||
|
4.09 
|
|
|
常規時段 (已結束)
|
|
|
|
|
||||||||||||
|
|
|
|
|
4.09
|
|
|
| 價值評估 |
|
盈利(現時/預測)
-0.33/-0.29
|
|
企業價值
248.61M
|
| 資產負債 |
|
每股賬面淨值
1.36
|
| 現金流量 |
|
現金流量率
--
|
| 損益表 |
|
收益
37.75M
|
|
每股收益
0.73
|
|
同行比較
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
同行比較之報價最少15分鐘延遲
|
業務概覽
|
|||
| Alpha Teknova Inc provides critical reagents that enable the discovery, development, and production of biopharmaceutical products such as drug therapies, novel vaccines, and molecular diagnostics. Its offer three product types: pre-poured media plates for cell growth and cloning; liquid cell culture media and supplements for cellular expansion; and molecular biology reagents for sample manipulation, resuspension, and purification. It derives key revenue from United States. |
